glp-1 obesity drug news Dozens of new drugs are coming: these are the ones to watch Half of GLP-1 users ditch

Both doses of orforglipron lowered blood sugar more than both doses of semaglutide

Moreover, growing medical tourism across Asian countries is attracting many international players to strengthen their presence through collaborations with local players

The future development and availability of biosimilars or generic formulations will be crucial for improving affordability and equitable access

Supported by emerging clinical evidence

These limitations include fatigue, shortness of breath, reduced exercise capacity, and limb swelling

is supported by the University of British Columbia Clinician Investigator Program and a Canadian Institutes of Health Research (CIHR) Canada Graduate ScholarshipMasters Award